XAV-939, a Tankyrase inhibitor, has been shown to promote ferroptosis in lung cancer cells by inducing the down-regulation of SLC7A11, and inhibiting the progression of lung cancer by down-regulating lncRNA MIR503HG, sponging miR-1273c and regulating SOX4 expression [189]. This evidence concerns the gene SOX4 and lung carcinoma.